Inlyta side effects - from FDA reports


Summary

In this review, we analyze Inlyta side effects by the time on the drug, gender and age of the people who have side effects while taking Inlyta. The review is based on 4,556 people who have side effects while taking the drug from FDA, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>


Inlyta

Inlyta has active ingredients of axitinib. (latest outcomes from Inlyta 4,558 users)

On Dec, 15, 2017

4,556 people who take Inlyta are studied.


Number of reports submitted per year:

Inlyta side effects.

Most common side effects over time *:

< 1 month:
  • death
  • stomatitis
  • renal cell carcinoma
  • vomiting
  • posterior reversible encephalopathy syndrome
  • weight decreased
  • hypertension
  • renal cancer
  • metastatic renal cell carcinoma
  • renal impairment
1 - 6 months:
  • death
  • weight decreased
  • renal cancer
  • renal cell carcinoma
  • stomatitis
  • metastatic renal cell carcinoma
  • hypertension
  • neoplasm malignant
  • diarrhoea
  • interstitial lung disease
6 - 12 months:
  • death
  • renal cancer
  • renal cell carcinoma
  • metastatic renal cell carcinoma
  • vomiting
  • weight decreased
  • osteonecrosis of jaw
  • drug ineffective
  • nausea
  • seizure
1 - 2 years:
  • renal cell carcinoma
  • metastatic renal cell carcinoma
  • death
  • renal cancer
  • stomatitis
  • disease progression
  • drug ineffective
  • neoplasm progression
  • nephrotic syndrome
  • renal impairment
2 - 5 years:
  • white blood cell count decreased
  • disease progression
  • viral infection
  • hypertension
  • interstitial lung disease
  • myocardial infarction
  • neoplasm malignant
  • nephrotic syndrome
  • proteinuria
  • renal cell carcinoma
5 - 10 years:
  • neoplasm malignant
10+ years:
  • osteonecrosis of jaw
not specified:
  • death
  • renal cancer
  • weight decreased
  • diarrhoea
  • neoplasm malignant
  • renal cell carcinoma
  • vomiting
  • nausea
  • fatigue
  • hypertension

Most common side effects by gender *:

female:
  • death
  • renal cancer
  • vomiting
  • weight decreased
  • diarrhoea
  • renal cell carcinoma
  • nausea
  • stomatitis
  • hypertension
  • fatigue
male:
  • death
  • renal cancer
  • weight decreased
  • renal cell carcinoma
  • diarrhoea
  • neoplasm malignant
  • vomiting
  • metastatic renal cell carcinoma
  • nausea
  • hypertension

Most common side effects by age *:

2-9:
  • pneumothorax
  • respiratory failure
10-19:
  • nausea
  • renal cancer
  • white blood cell count increased
20-29:
  • death
  • diarrhoea
  • leukoencephalopathy
  • pain
  • pneumonia
  • pyrexia
  • renal cancer
  • renal cell carcinoma
  • weight decreased
30-39:
  • death
  • renal cancer
  • vomiting
  • weight increased
  • blood triglycerides increased
  • glycosuria
  • lymph node pain
  • metastatic renal cell carcinoma
  • myalgia
  • nausea
40-49:
  • death
  • renal cancer
  • renal cell carcinoma
  • vomiting
  • weight decreased
  • metastatic renal cell carcinoma
  • nausea
  • pulmonary oedema
  • diarrhoea
  • posterior reversible encephalopathy syndrome
50-59:
  • death
  • renal cancer
  • renal cell carcinoma
  • weight decreased
  • vomiting
  • nausea
  • diarrhoea
  • neoplasm malignant
  • stomatitis
  • hypertension
60+:
  • death
  • renal cancer
  • weight decreased
  • diarrhoea
  • renal cell carcinoma
  • vomiting
  • stomatitis
  • metastatic renal cell carcinoma
  • nausea
  • hypertension

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

Want to find out more about the FDA reports used in the study? You can request them from FDA.

Are you taking Inlyta?

Expand the study to include reports from both FDA and eHealthMe

Inlyta side effects from FDA and eHealthMe reports

Related studies

All Inlyta side effects from A to Z

a b c d e f g h i j k l m n o p q r s t u v w x y z

On eHealthMe, Inlyta (axitinib) is often used to treat renal cell carcinoma. Find out below the conditions the drugs are used for and how effective they are.

You may be interested in these reviews

More reviews for: Inlyta